Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Globalization, Three Quarters of Serious Inspection Issues FDA Found Were in US

Executive Summary

Interactive map, charts provide details on our analysis of FDA 2009-2014 inspection results data showing that even as the agency responded to the threat of poor drug quality abroad, it was more successful at finding serious quality issues during its much more numerous domestic inspections.

Advertisement

Related Content

US FDA’s New Compliance Chief Donald Ashley Brings International Law Enforcement Experience
After Recusal, Schnedar Leaving CDER Compliance Office
FDA Inspections Ombudsman Could Help Foreign Manufacturers
FDA Mutual Reliance with EU on Inspections Is Slow Going
Hamburg Promises Quicker Enforcement as FDA Spews Warning Letters
Electronic Registration to Aid FDA's Quest for Enhanced Global Oversight

Topics

Advertisement
UsernamePublicRestriction

Register

PS057496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel